Theolytics
theolytics.com
Actively hiring
Cell & Gene Therapy
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
51-200
employees, estimated range
Grants
$5.8M
1 grant · CORDIS
Backers
4
Epidarex Capital, M Ventures
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 1
Won a grant $5.8M · CORDIS
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Jun 2026 | $5.8M | — | CORDIS |
Backed byfrom the funds' portfolios and accelerator catalogs
Epidarex Capital 
M Ventures 
Sound Bioventures 
Taiho Ventures Similar startupsby what they do, their industry and backers
Kytopen is accelerating access to the next generation of cell therapies through scalable genome engineering by solving manufacturing…
Designer cell therapies for pets first and their people next.
Redefining Complement Therapies. Complement Therapeutics is a clinical-stage biotechnology company advancing precision therapies for…
PINPOINT DNA MEDICINES FOR CHRONIC DISEASES. Next generation precision molecular therapies to tackle, in a safe and durable way, chronic…
We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
At cellvie, we are pioneering Therapeutic Mitochondria Transplantation, a novel treatment approach aimed at the cellular energy metabolism.
Overview
Our Adenovo™ platform and 100-million-variant library move us from discovery to impact. With THEO-260 as our lead programme, our world-class team is applying world-leading science to expand access to innovative therapies that promise lasting benefit.
Financials
Total raised
$5.8M
Latest round
Grant
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Grant | 2026 | $5.8M | Details |